Denali Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. 

CEO
Ryan J. Watts
CEORyan J. Watts
Employees
503
Employees503
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
503
Employees503

DNLI Key Statistics

Market cap
3.11B
Market cap3.11B
Price-Earnings ratio
-6.81
Price-Earnings ratio-6.81
Dividend yield
Dividend yield
Average volume
1.99M
Average volume1.99M
High today
$20.53
High today$20.53
Low today
$19.30
Low today$19.30
Open price
$19.45
Open price$19.45
Volume
1.92M
Volume1.92M
52 Week high
$23.77
52 Week high$23.77
52 Week low
$12.58
52 Week low$12.58

Stock Snapshot

The current Denali Therapeutics(DNLI) stock price is $19.30, with a market capitalization of 3.11B. The stock trades at a price-to-earnings (P/E) ratio of -6.81.

On 2026-05-09, Denali Therapeutics(DNLI) stock traded between a low of $19.30 and a high of $20.53. Shares are currently priced at $19.30, which is 0.0% above the low and -6.0% below the high.

The Denali Therapeutics(DNLI)'s current trading volume is 1.92M, compared to an average daily volume of 1.99M.

During the past year, Denali Therapeutics(DNLI) stock moved between $12.58 at its lowest and $23.77 at its peak.

During the past year, Denali Therapeutics(DNLI) stock moved between $12.58 at its lowest and $23.77 at its peak.

DNLI News

Benzinga 2d
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'

Claude AI Makes Bold Denali Therapeutics Earnings Bet The AI-run portfolio, known as The Claude Portfolio, allocated roughly 4.82% of its $50,000 fund to Denali...

Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Simply Wall St 5d
Denali Therapeutics Is Down 6.4% After Takeda Exits DNL593 Partnership - What's Changed

In early May 2026, Denali Therapeutics announced that partner Takeda will terminate their collaboration on DNL593 for strategic reasons unrelated to efficacy or...

Denali Therapeutics Is Down 6.4% After Takeda Exits DNL593 Partnership - What's Changed

Analyst ratings

95%

of 19 ratings
Buy
94.7%
Hold
5.3%
Sell
0%

People also own

Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.